[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 27, Issue 1 (Scientific Journal of Kurdistan University of Medical Sciences 2022) ::
SJKU 2022, 27(1): 101-114 Back to browse issues page
Discovery of Serine/Threonine-Protein Kinase 4 Inhibitor by Molecular Docking and Molecular Dynamics Studies for Treatment of Diabetes
Fatemeh Abdi1 , Monireh Movahedi2 , Mir Mohammad Alavi Nikje3 , Sako Mirzaie 4
1- Ph.D. Candidate of Biochemistry, Department of Cellular and Molecular Biology, Tehran North Branch, Islamic Azad University, Tehran, Iran
2- Assistant Professor of Biochemistry, Department of Cellular and Molecular Biology, Tehran North Branch, Islamic Azad University, Tehran, Iran.
3- Professor of Organic Chemistry, Department of Chemistry, Faculty of Science, Imam Khomeini International University, Tehran, Iran.
4- Assistant Professor of Biochemistry, Department of Biochemistry, Sanandaj Branch, Islamic Azad University, Sanandaj, Iran. , s.mirzaie@utoronto.ca
Abstract:   (772 Views)
Background and Aim: Nowadays, diabetes mellitus is a major challenge for human health. Serine/threonine-protein kinase 4 (STK4) is a main regulator of pancreatic β-cell death and dysfunction, and its over activation can lead to type 1 and type 2 diabetes. Deficiency of STK4 restores functional β-cells and normoglycemia. In the current study, for the first time, we used molecular modeling to discover a potent STK4 inhibitor.
Materials and Methods: In this study, among 51220 molecules in ZINC database, we used the molecular docking method for virtual screening process to select the potent and effective inhibitors against STK4. We used Desmond software for molecular dynamics (MD) simulations studies of the structures with the lowest free binding energy for 100 ns. The ADME properties of the selected compounds were calculated by Qikprop software.
Results: Virtual screening results showed that compounds with ZINC ID of ZINC95918625, ZINC85569233, ZINC03874317, ZINC00105086 and ZINC14819359 can be considered as STK4 inhibitors. Among these compounds, ZINC95918625 had the lowest free binding energy (-11.67 kcal/mol). After the 100 ns MD studies, ZINC95918625 interacted with STK4 residues of Lys59, Glu73, Cys105, and Gly153 via hydrogen bonding. ADME analysis exhibited that all pharmaco-kinteic parameters of ZINC95918625 were within the reasonable range.
Conclusion: Our study can provide valuable information about new inhibitors for diabetes treatment. The findings of this study indicated that ZINC95918625 molecule could be used as a novel STK4 inhibitor in the future studies.
Keywords: Diabetes, Serine/Threonine-Protein Kinase 4, Virtual screening, Molecular dynamics
Full-Text [PDF 821 kb]   (137 Downloads)    
Type of Study: Original Research | Subject: Biochemistry and Clinical Laboratory
Received: 2020/11/29 | Accepted: 2021/06/14 | Published: 2022/04/19
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Abdi F, Movahedi M, Alavi Nikje M M, Mirzaie S. Discovery of Serine/Threonine-Protein Kinase 4 Inhibitor by Molecular Docking and Molecular Dynamics Studies for Treatment of Diabetes. SJKU. 2022; 27 (1) :101-114
URL: http://sjku.muk.ac.ir/article-1-6460-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 27, Issue 1 (Scientific Journal of Kurdistan University of Medical Sciences 2022) Back to browse issues page
مجله علمی دانشگاه علوم پزشکی کردستان Scientific Journal of Kurdistan University of Medical Sciences
مجله علمی دانشگاه علوم پزشکی کردستان Scientific Journal of Kurdistan University of Medical Sciences
Persian site map - English site map - Created in 0.04 seconds with 29 queries by YEKTAWEB 4457